December 6, 2025 | Bengaluru, Karnataka
Biocon Limited today announced a massive ₹11,450 crore capital investment plan aimed at integrating and expanding its biologics business. The initiative focuses on boosting research, manufacturing capabilities, and global market reach for its biologic therapies.
Company officials highlighted that the plan will enhance production capacity, streamline operations, and accelerate innovation in complex biologics. Analysts view this move as a strategic step to strengthen Biocon’s position in the global biopharmaceutical sector.
Leave a Reply